Los Angeles, CANCT06615752Now EnrollingIRB Ready

Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trial in Los Angeles, CA

Access cutting-edge metastatic castration-resistant prostate cancer (mcrpc) treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Charles Drew University of Medicine and Science

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access metastatic castration-resistant prostate cancer (mcrpc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic castration-resistant prostate cancer (mcrpc) treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this metastatic castration-resistant prostate cancer (mcrpc) clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Metastatic Castration-resistant Prostate Cancer (mCRPC) Study in Los Angeles

The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination. Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.

Sponsor: Charles Drew University of Medicine and Science

Who Can Participate

Inclusion Criteria

Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male patients 18 years or older
Diagnosed with metastatic prostate cancer
History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
Clinical decision to start doc infusion with prednisone treatment
Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³)
Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN)
Adequate renal function (serum creatinine level within normal limits)
At least a 6-month or greater life expectancy
Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention

Exclusion Criteria

Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
Any comorbid condition that would preclude the administration of docetaxel/prednisone
Ongoing alcohol abuse
Significant medical or psychiatric conditions that would make the patient a poor protocol candidate
Prior allergic reaction to tea, tea products or quercetin supplements
Allergies to multiple food items or nutritional supplements

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06615752) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Castration-resistant Prostate Cancer (mCRPC) Treatment Options in Los Angeles, CA

If you're searching for metastatic castration-resistant prostate cancer (mcrpc) treatment options in Los Angeles, CA, this clinical trial (NCT06615752) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic castration-resistant prostate cancer (mcrpc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic castration-resistant prostate cancer (mcrpc) clinical trials near you to find additional studies recruiting in your area.

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA